ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1821

Leptin, Adiponectin, and Resistin As Serum Markers of Fatigue in Systemic Lupus Erythematosus: A Pilot Study

Mary Mahieu1, Grace Ahn2, Joan S. Chmiel3, Dorothy D. Dunlop4, Irene Helenowski3, Pamela Semanik5, Jing Song4, Rowland W. Chang3 and Rosalind Ramsey-Goldman6, 1Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, 2Rheumatology, Falls Medical Specialists, Baltimore, MD, 3Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, 4Institute for Healthcare Studies, Northwestern University Feinberg School of Medicine, Chicago, IL, 5Nursing, Rush University College of Nursing, Chicago, IL, 6Northwestern University Feinberg School of Medicine, Chicago, IL

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Adipokines, fatigue and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2015

Title: Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Fatigue, a common symptom in systemic lupus erythematosus (SLE) patients, is ameliorated by physical activity. Adiposity and adipokines may be associated with patient-reported fatigue. We describe associations between adipokines (leptin, adiponectin, and resistin) and fatigue, physical activity, and SLE disease activity.

Methods: We examined adipokines, self-reported fatigue, and objective physical activity in 129 patients meeting ACR revised criteria for definite SLE from the Activity in Lupus to Energize and Renew (ALTER) study. Body mass index (BMI), disease activity (Safety of Estrogens in Systemic Lupus Erythematosus National Assessment – Systemic Lupus Erythematosus Disease Activity Index [SELENA-SLEDAI]), and disease damage (Systemic Lupus International Collaborating Clinics Damage Index [SDI]) were measured. Fatigue was assessed by the Fatigue Severity Scale (FSS). A triaxial accelerometer was worn for 7 days, and physical activity was estimated by total accelerometer vector magnitude (VM) counts. Six patients with <4 valid days of accelerometer wear were excluded from physical activity analyses. Leptin, adiponectin, and resistin were measured in stored serum with a Luminex bead-based assay. Adipokine data were logarithmically transformed for inclusion in linear regression models describing relationships between FSS and adipokines. Spearman correlation coefficients assessed associations between adipokines, physical activity, and SELENA-SLEDAI.

Results: Participants were female (94%), Caucasian (53%), and mean age 45.5 years (SD 10.9). BMI was 28.1 kg/m2 (8.2). SELENA-SLEDAI was 2.4 (2.8) and SDI was 1.7 (2.2). FSS score was 4.4 (1.6), consistent with clinically relevant fatigue. Mean adipokine levels were: leptin 44.2 ng/ml (47.6), adiponectin 13.5 μg/ml (10.8) and resistin 1.9 ng/ml (1.5). No significant associations were found between adipokines and FSS in any of the regression models (Table 1). BMI ≥ 30 kg/m2 (obesity) was associated with FSS in adjusted models (p <0.05, data not shown). Weak correlations between leptin, adiponectin, and physical activity, and between adiponectin and SELENA-SLEDAI score, were not significant after adjusting for BMI (Table 2).

Conclusion: No relationships were found between adipokines and fatigue in SLE patients. This study demonstrates that adipokines are correlated with physical activity (leptin and adiponectin) and SLE disease activity (adiponectin), but most of these associations can be explained by BMI.

 

Table 1. Linear regression model results for FSS (dependent variable) and each adipokine measure (predictor variable, natural log scale)

 

Adjustment Variables

Regression coefficient

Leptin

Adiponectin

Resistin

Model 1

Unadjusted

β

0.25

-0.11

0.36

95% CI

-0.05, 0.54

-0.53, 0.32

-0.08, 0.81

Model 2

BMI, age, sex, race/ethnicity

β

-0.12

0.08

0.32

95% CI

-0.59, 0.35

-0.39, 0.55

-0.12, 0.76

Model 3

Model 2 plus

SELENA-SLEDAI

β

-0.17

0.02

0.26

95% CI

-0.65, 0.30

-0.46, 0.50

-0.19, 0.72

Model 4

Model 2 plus total accelerometer VM counts and wear time (n=123)

β

-0.14

0.26

0.24

95% CI

-0.61, 0.32

-0.21, 0.72

-0.21, 0.70

CI = confidence interval

 

Table 2. Spearman correlations for adipokines, physical activity, and SLE disease activity

 

Adjustment Variables

Correlation coefficient

Leptin

Adiponectin

Resistin

Total accelerometer VM counts (n=123)

Accelerometer wear time

r

-0.25

0.20

-0.07

95% CI

-0.41, -0.08

0.02, 0.36

-0.25, 0.10

Accelerometer wear time plus BMI

r

-0.06

0.11

-0.04

95% CI

-0.24, 0.12

-0.08, 0.28

-0.22, 0.14

SELENA-SLEDAI (n=129)

Unadjusted

r

0.02

0.18

0.08

95% CI

-0.15, 0.19

0.01, 0.34

-0.09, 0.25

BMI

r

0.16

0.15

0.09

95% CI

-0.02, 0.32

-0.02, 0.32

-0.08, 0.26

Bolded r-values (95% CI) indicate statistical significance.


Disclosure: M. Mahieu, None; G. Ahn, None; J. S. Chmiel, None; D. D. Dunlop, None; I. Helenowski, None; P. Semanik, None; J. Song, None; R. W. Chang, None; R. Ramsey-Goldman, None.

To cite this abstract in AMA style:

Mahieu M, Ahn G, Chmiel JS, Dunlop DD, Helenowski I, Semanik P, Song J, Chang RW, Ramsey-Goldman R. Leptin, Adiponectin, and Resistin As Serum Markers of Fatigue in Systemic Lupus Erythematosus: A Pilot Study [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/leptin-adiponectin-and-resistin-as-serum-markers-of-fatigue-in-systemic-lupus-erythematosus-a-pilot-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/leptin-adiponectin-and-resistin-as-serum-markers-of-fatigue-in-systemic-lupus-erythematosus-a-pilot-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology